SLU-PP-332 – User Manual & Research Handling Guide

1

Product Overview

SLU-PP-332 is a synthetic small-molecule compound studied as an estrogen-related receptor (ERR) agonist, particularly targeting ERRα, ERRβ, and ERRγ in metabolic research models.

It has gained interest in experimental settings for its potential influence on:

  • Skeletal muscle metabolism
  • Mitochondrial biogenesis
  • Fat oxidation pathways
  • Exercise-mimetic research models

Research Applications

  • Oxidative metabolism studies
  • Mitochondrial density investigations
  • Endurance physiology research
  • Metabolic flexibility models
  • Fat oxidation and energy expenditure research

Disclaimer: SLU-PP-332 is for research and experimental use only. It is not FDA-approved for therapeutic or human use.

2

Forms Available

Research Powder

Raw compound intended for laboratory formulation in research settings.

Capsule (Research Grade)

Pre-measured investigational format for controlled dosing in studies.

Solution (Research Prep)

Laboratory-prepared dosing solution for research applications.

Note

Concentration and preparation vary by supplier and specific research protocol.

3

Mechanism of Action (Research)

SLU-PP-332 is studied for its ability to:

  • Activate estrogen-related receptors (ERRs)
  • Promote transcription of genes involved in oxidative phosphorylation
  • Enhance mitochondrial function in skeletal muscle models
  • Increase fatty acid oxidation pathways
  • Mimic certain metabolic adaptations seen with endurance training

Most data currently derives from animal models and in vitro research.

4

Dosage Protocol (Investigational Reference)

Important Safety Notice

There is no FDA-approved dosage for SLU-PP-332, and safe human dosing has not been established.

Dosing Determination

All dosing must be guided by:


  • A qualified principal investigator

  • Institutional research approval (IRB/IACUC where applicable)

  • Product-specific Certificate of Analysis (COA) data

  • Preclinical safety evaluation

Protocol-Defined Dosing


  • Oral (Research Model): Dose and frequency are protocol-defined, based on metabolic endpoints.

  • Injectable (Preclinical Models): Dose and frequency are protocol-defined, used only in approved animal studies.

Research Note

Preclinical animal studies often use mg/kg bodyweight calculations, which do not translate directly to human dosing.

5

Cycle Framework (Research Models)

Initiation

A protocol-defined phase used to evaluate tolerance and metabolic response at the start of the study.

Active Study Phase

A protocol-defined phase focused on tracking mitochondrial function and endurance outcomes.

Washout Period

A protocol-defined interval between research cycles to allow physiological systems to reset.

Note

Phase duration varies depending on research objectives.

6

Reconstitution Instructions (If Lyophilized)

Laboratory Handling Notes

  • Use appropriate PPE and follow institutional SOPs
  • Prepare solutions under sterile or controlled laboratory conditions
  • Label preparations with concentration, preparation date, and storage requirements
  • Avoid exposure to excessive heat, light, or moisture

Exact preparation methods should be defined within study protocols.

7

Administration Guidelines (Research Handling)

Route of administration must follow approved research design.
Consistent timing is typically used in metabolic pathway studies.

Do not administer outside controlled research environments.

8

Storage Guidelines

Powder

Store in a cool, dry environment and protect from light. Shelf life is per manufacturer or COA specifications.

Prepared Solution

Keep refrigerated at 2–8°C unless otherwise specified. Shelf life is protocol-defined.

Protection Guidelines

Protect from heat, light, moisture, and contamination to preserve quality.

Safety Note

Discard the material if it shows signs of degradation or contamination.

9

Safety & Handling

  • Research use only
  • Not for therapeutic application
  • Long-term human safety data is not established
  • Potential research observations in preclinical models may include:
  • Increased metabolic rate
  • Altered lipid utilization
  • Changes in endurance performance markers

Systemic ERR activation may affect multiple organ systems in investigational models.

Maintain proper chemical handling and disposal procedures.

Keep out of reach of children.

10

Quick Reference

Compound: SLU-PP-332
Category: Metabolic Research / ERR Agonist
Delivery Model: Protocol-defined research model
Dose Range: Not established for general use
Cycle: Protocol-defined research designs
Storage: Protect from heat/light; follow COA guidelines